Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.

Minerva Neurosciences Trading Up 0.2 %

NASDAQ:NERV opened at $2.67 on Thursday. The firm has a market capitalization of $18.67 million, a price-to-earnings ratio of -0.60 and a beta of 0.14. Minerva Neurosciences has a 1-year low of $2.26 and a 1-year high of $13.49. The business’s fifty day moving average price is $2.72 and its 200 day moving average price is $2.80.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities analysts forecast that Minerva Neurosciences will post -2.26 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.